Key statistics
On Thursday, Akero Therapeutics Inc (0K4:STU) closed at 29.42, -18.28% below its 52-week high of 36.00, set on Mar 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 28.95 |
---|---|
High | 29.42 |
Low | 28.95 |
Bid | 29.53 |
Offer | 30.02 |
Previous close | 28.87 |
Average volume | 62.22 |
---|---|
Shares outstanding | 69.80m |
Free float | 59.12m |
P/E (TTM) | -- |
Market cap | 2.18bn USD |
EPS (TTM) | -3.75 USD |
Data delayed at least 15 minutes, as of Nov 21 2024.
More ▼
- Akero Therapeutics to Showcase New Analyses of Phase 2b HARMONY Study in Presentations at 75th Annual AASLD The Liver Meeting® 2024
- Akero Therapeutics to Present at the Jefferies London Healthcare Conference
- Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024
- Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference
- Akero Therapeutics Announces First Patient Dosed in Phase 3 SYNCHRONY Outcomes Study of Efruxifermin in Patients with Compensated Cirrhosis Due to MASH
- Akero Therapeutics to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
- Akero Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Akero Therapeutics Announces Initiation of Phase 3 SYNCHRONY Outcomes Trial of Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
- Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024
More ▼